At ACR Convergence 2025, researchers from Toronto and NYU reported that PsA patients starting GLP-1 receptor agonists had significant improvements in joint counts, CRP, pain scores, and DAPSA disease activity scores within one year of treatment. Whats interesting is that you dont seem to need a large dose to see these benefits
This compound has gained significant attention in preclinical and early clinical research due to its promising effects on body weight reduction, insulin sensitivity improvement, and lipid profile enhancement
However, weight isnt an accurate indicator of health, and pathologizing fatness only reinforces fatphobia, diet culture, and healthism
What separates out that patient from the person who's coming in next, or you just saw, who has the same body mass index
GLP-1 medications can cause side effects
The appetite suppression resulted in her shedding pounds quickly, at first